Mr. Peter Puccetti reports

COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING

Cosciens Biopharma Inc. has published a new corporate presentation, now available on its website.

The presentation provides an overview of the company and its operating subsidiaries, following the recent acquisition of Nualtis Corp. and includes information relating to the continuing private placement of 15 per cent unsecured convertible debentures.

To date, Cosciens has issued approximately $12-million (U.S.) aggregate principal amount of debentures and based on investor feedback and engagement, management is optimistic about the ability of the company to raise additional funds in the coming weeks, subject to the maximum principal amount of $20-million (U.S.). Unless the maximum amount is issued sooner, the company intends to continue marketing the debentures through mid-November.

Funds raised to date in the offering, along with Cosciens's pre-existing cash balance, are already sufficient to pay the remaining $6-million (U.S.) due to AtaiBeckley in March, 2027, as a deferred purchase price payment for the acquisition of Nualtis. However, Cosciens strives to be well capitalized with excess cash at all times. If the full $20-million (U.S.) is raised in the aggregate and Cosciens's shareholders approve the conversion of the debentures into common shares of Cosciens at a shareholders' meeting expected to be held in December, Cosciens estimates that its pro forma market capitalization would be approximately $27-million (U.S.) and the company would have over $7-million (U.S.) of cash on hand with no outstanding indebtedness (assuming conversion in full), after making the deferred payment in March.

About Cosciens Biopharma Inc.

Cosciens Biopharma is a holding company operating through its subsidiaries, including Ceapro Inc. and Nualtis.

Ceapro is focused on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources, using proprietary manufacturing and extraction technologies. Ceapro's primary active ingredient business activities relate to the development and commercialization of natural products for the personal care, cosmetic, human and animal health industries.

Nualtis is a specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies. Its business model includes pharmaceutical formulation development, analytical and regulatory support services, contract development and manufacturing activities, partner-sponsored development programs, and commercial product manufacturing.

The company's common shares are listed on the Toronto Stock Exchange under the symbol CSCI and are listed and posted for trading on the OTCQB Venture Market under the symbol CSCIF.

We seek Safe Harbor.